KANSAS CITY, Kan.
March 26, 2013
Aratana Therapeutics, Inc.
, a biopharmaceutical company focused on licensing, developing and commercializing innovative prescription medications for cats and dogs (companion animals), today announced it has expanded its relationship with
, DVM, as a consultant to the company who will lead drug evaluation and development in Europe. Dr. Lachaud is a seasoned animal health executive whose work has led to significant companion animal health product approvals in Europe. Additionally, Aratana expanded its U.S. drug development team to include
Laura Simon Treml
, VMD, Ph.D., as Director of Drug Development and
Glenda L. Armintrout
as Senior Research Associate, each of whom bring significant expertise in overseeing clinical programs in companion animals.
, DVM, Ph.D., Head of Aratana's Drug Evaluation and Development, stated, "We're delighted that Marie-Paul has expanded her role with us. Her engagement represents Aratana's first presence outside of
the United States
, and we could not ask for a better suited professional to lead our development efforts for the European market. We are also fortunate to add Laura and Glenda to our team, as we focus on execution of our clinical development programs for our current drug candidates. Given the strength of their backgrounds in companion animal drug development, we believe we will be well served by their expertise."
Marie-Paul Lachaud, DVM
Dr. Lachaud, whose prior experience focused on international development for animal drugs, was the European animal health director at ICON Clinical Research in
from 2000 to 2008. In 1990, she co-founded PROTOCOLE, the first European veterinary consultancy and contract research organization focused on clinical drug development and regulatory affairs, which was acquired by ICON in 2000.
Primarily focused on transitioning human drugs to meet the needs of veterinary medicine, Dr. Lachaud's work has resulted in significant companion animal health product approvals in
and the U.S. in a number of innovative therapeutic areas, including reproduction, atopic dermatitis, chronic heart failure, wound healing, chronic kidney disease, pain, obesity, oncology, cognitive dysfunction and anxiety-related disorders.
As Head of Business and Product Development Europe, her responsibilities include coordinating the European Regulatory process for Aratana's products and running the company's in-licensing and out-licensing activities in
She received her veterinary degree from Alfort National Veterinary School in
and her doctorate in veterinary medicine from the University of
Laura Simon Treml, VMD, Ph.D.
Prior to her appointment at Aratana, Dr. Treml led clinical development programs for dogs and cats and managed the Companion Animal Efficacy group at Bayer Animal Health. Earlier in her career, she practiced small animal medicine and surgery on the East Coast for nine years.
As Director of Drug Development at Aratana, Dr. Treml's responsibilities include designing and managing several of the company's drug development programs and scientifically evaluating potential new in-licensing drug candidates.